Industry Risks Remain In Central And Eastern Europe's Q211 BERs

BMI View: The attractiveness of Central and Eastern Europe (CEE) to multinational pharmaceutical companies has increased. The region scored 51.6 out of 100 in BMI's Pharmaceutical & Healthcare Business Environment Ratings (BERs) for Q211. While the outlook for individual markets is mixed compared with more developed markets, CEE's appeal stems from superior pharmaceutical expenditure growth forecasts. However, significant operating risks limit the region's overall attractiveness. BMI believes that the fundamental risk for pharmaceutical companies operating in CEE is the outcome of various drug market reforms, as the full impact of these measures will not be realised until mid-2011.

To read the full article, please choose one of the following options: